Page last updated: 2024-12-06

opromazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Opromazine is a phenothiazine derivative that was originally developed as an antipsychotic medication. It has been studied for its potential to treat a variety of conditions, including schizophrenia, anxiety, and nausea. Opromazine's mechanism of action involves blocking dopamine receptors in the brain. It has been shown to have antiemetic effects, and it is used in the treatment of postoperative nausea and vomiting. However, opromazine has also been associated with a number of side effects, including sedation, dizziness, and extrapyramidal symptoms. Due to the availability of newer, more effective and safer antipsychotic drugs, opromazine is no longer widely used in clinical practice.'

opromazine: RN given refers to parent cpd; structure in 9th ed, Merck Index, #6697 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID70413
CHEMBL ID823
CHEBI ID125461
SCHEMBL ID1155596
MeSH IDM0087461

Synonyms (60)

Synonym
wln: t c666 bn isj b3n1&1 eg io
chlorpromazine-s-oxyd
2-chloro-10-[3-(dimethylamino)propyl]phenothiazine-5-oxide
chloropromazine sulfoxide
sulfoxide of chlorpromazine
opromazin
phenothiazine, oxide
chlorpromazine sulphoxide
cpz-o
transedon
chlorpromazine sulfoxide
nsc-170990
opromazine
nsc170990
secotil
chlorpromazine sulfoxide hydrochloride
969-99-3
np 956
5293 rp
oxychlorpromazine
10h-phenothiazine-10-propanamine,n-dimethyl-, 5-oxide
chlorpromazine-s-oxide
ba 2835
phenothiazine, 2-chloro-10-(3-(dimethylamino)propyl)-, 5-oxide
10h-phenothiazine-10-propanamine, 2-chloro-n,n-dimethyl-, 5-oxide
phenothiazine, 2-chloro-10-(3-(dimethylamino)propyl)-, oxide
5-oxychlorpromazine
phenothiazine, 2-chloro-10-(3-(dimethylamino)propyl)-, sulfoxide
brn 0307255
10-(gamma-dimethylaminopropyl)-3-chlorophenothiazine 9-oxide
2-chloro-10-(3-(dimethylamino)propyl)phenothiazine-5-oxide
nsc 170990
CHEBI:125461
CHEMBL823
016u10pn9n ,
unii-016u10pn9n
bdbm50408507
cpz-so
ba-2835
2-chloro-10-(3-(dimethylamino)propyl)phenothiazine 5-oxide
2-chloro-10-[3-(dimethylamino)propyl]-5lambda4-phenothiazin-5(10h)-one
chlorpromazine hydrochloride impurity a [ep impurity]
opromazine [mi]
10-(.gamma.-dimethylaminopropyl)-3-chlorphenothiazine 9-oxide
2-chloro-n,n-dimethyl-10h-phenothiazine-10-propanamine 5-oxide
BRD-A94494639-001-01-6
SCHEMBL1155596
QEPPAOXKZOTMPM-UHFFFAOYSA-N
10-(.gamma.-dimethylaminopropyl)-3-chlorophenothiazine 9-oxide
3-(2-chloro-5-oxido-10h-phenothiazin-10-yl)-n,n-dimethyl-1-propanamine #
Q27216080
chlorpromazine sulphoxide 1.0 mg/ml in methanol
3-(2-chloro-10h-phenothiazin-10-yl)-n,n-dimethylpropan-1-amine s-oxide (chlorpromazine sulfoxide)
chlorpromazine sulfoxide; opromazine; 3-(2-chloro-10h-phenothiazin-10-yl)-n,ndimethylpropan-1-amine s-oxide; 2-chloro-10-[3-(dimethylamino)propyl]phenothiazine 5-oxide
chlorpromazine ep impurity a
DTXSID40871817
2-chloro-10-[3-(dimethylamino)propyl]-10h-phenothiazin-5-ium-5-olate
2-chloro-10-[3-(dimethylamino)propyl]-10h-5lambda4-phenothiazin-5-one
3-[(5r)-2-chloro-5-oxophenothiazin-10-yl]-n,n-dimethylpropan-1-amine
EN300-262069

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The discrepancies observed were not only due to nonspecificity of the immunoassay procedures employed, but also to a lack of rigorous specificity of the HPLC procedure in plasma samples from dosed humans."( Therapeutic monitoring of chlorpromazine. IV: Comparison of a new high-performance liquid chromatographic method with radioimmunoassays for parent drug and some of its major metabolites.
Chakraborty, BS; Cooper, JK; Gurnsey, T; Hawes, EM; Hubbard, JW; McKay, G; Midha, KK; Yeung, PK, 1987
)
0.27
"Thirty-seven newly admitted schizophrenic patients were treated with an open and flexible dosage of chlorpromazine for 3 months after receiving a test dose."( Prediction of drug responses in schizophrenia: a method using a test dose of chlorpromazine.
Minami, H; Miyahara, A; Nakahara, T; Nakane, Y, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenothiazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Trypanothione reductaseTrypanosoma cruziIC50 (µMol)76.60005.80005.80005.8000AID214488
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium channel subfamily K member 2Homo sapiens (human)EC50 (µMol)2.70000.18702.72248.1800AID1802150
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
cardiac ventricle developmentPotassium channel subfamily K member 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayPotassium channel subfamily K member 2Homo sapiens (human)
memoryPotassium channel subfamily K member 2Homo sapiens (human)
response to mechanical stimulusPotassium channel subfamily K member 2Homo sapiens (human)
response to axon injuryPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of cardiac muscle cell proliferationPotassium channel subfamily K member 2Homo sapiens (human)
cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium channel subfamily K member 2Homo sapiens (human)
cochlea developmentPotassium channel subfamily K member 2Homo sapiens (human)
positive regulation of cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of DNA biosynthetic processPotassium channel subfamily K member 2Homo sapiens (human)
stabilization of membrane potentialPotassium channel subfamily K member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
outward rectifier potassium channel activityPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion leak channel activityPotassium channel subfamily K member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membranePotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
cell surfacePotassium channel subfamily K member 2Homo sapiens (human)
apical plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
neuronal cell bodyPotassium channel subfamily K member 2Homo sapiens (human)
calyx of HeldPotassium channel subfamily K member 2Homo sapiens (human)
astrocyte projectionPotassium channel subfamily K member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID205269Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1182134Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of kanamycin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID75299Inhibitory activity against human erythrocyte glutathione reductase; '*' indicates No inhibition1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
AID214488Inhibitory activity against recombinant Trypanosoma cruzi (Trypanosoma cruzi) Trypanothione reductase1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1182131Antitubercular activity against Mycobacterium smegmatis by checkerboard assay2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182135Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of spectinomycin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID103232Anti MDR activity was expressed as MDR ratio or MDR fold reversal in doxorubicin resistant human breast carcinoma tumor cell line MCF-7/DOX1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study.
AID1802150TREK1 Assay from Article 10.1111/cbdd.12810: \\Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.\\2016Chemical biology & drug design, Dec, Volume: 88, Issue:6
Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (73.17)18.7374
1990's5 (12.20)18.2507
2000's1 (2.44)29.6817
2010's4 (9.76)24.3611
2020's1 (2.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.22 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.44%)6.00%
Case Studies2 (4.88%)4.05%
Observational0 (0.00%)0.25%
Other38 (92.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]